The math reveals an uncomfortable truth: GLP-1 utilization tells only part of the metabolic health story.
New analysis from the Peterson-KFF Health System Tracker examined GLP-1 utilization patterns across employer-sponsored insurance plans. The headline finding: 15% of covered adults used a GLP-1 in 2023. But with 42% of U.S. adults meeting obesity criteria, a significant portion of the workforce with obesity isn't accessing these medications.
This gap represents a strategic challenge for employers. While expanding GLP-1 coverage dominates benefits discussions, the larger question remains unaddressed: how do you support the substantial population with obesity who aren't on—or won't stay on—medication?
The Overlooked Population
This population isn't a monolith. Some don't meet the specific clinical criteria for GLP-1s beyond BMI alone. Others face access barriers despite coverage. Many experience side effects or supply disruptions. And a substantial group prefers non-pharmaceutical approaches as their first intervention.
Recent employer surveys show that 77% of large employers now cover GLP-1s for obesity. But coverage alone doesn't equal comprehensive metabolic health support. The employees not taking GLP-1s still face the same chronic disease risks—they're just not visible in your specialty pharmacy reports.
The Cost of Binary Thinking
The current approach creates a benefits cliff. Employees either qualify for expensive pharmacotherapy or receive minimal support. This binary model ignores decades of evidence on metabolic health interventions.
The NIH Diabetes Prevention Program demonstrated that lifestyle intervention reduced progression to diabetes by 58% among people with prediabetes—without medication. While this specific population differs from the general obesity cohort, it illustrates the potential impact of structured behavioral programs.
For self-funded employers, employees with untreated obesity face doubled healthcare costs compared to those at healthy weight. Whether they're on GLP-1s or not, the metabolic health of your entire workforce drives medical spend, productivity, and disability claims.
Beyond Medication-Only Strategies
Benefits leaders need multi-modal approaches that serve all employees with metabolic health needs:
Expand the definition of treatment success. Track not just GLP-1 utilization but how many employees with obesity receive any evidence-based weight management support. The gap between obesity prevalence and intervention access is your real opportunity metric.
Build maintenance into the model. With 40-50% of GLP-1 users discontinuing within 12 months, post-medication support isn't optional—it's essential for protecting your pharmaceutical investment.
Deploy scalable digital programs. Evidence-based digital interventions can reach employees who aren't candidates for medication, aren't ready for it, or need support during and after treatment. The infrastructure requirements are minimal compared to high-touch clinical programs.
Create clear pathways, not just coverage. Employees need to understand their options across the weight management continuum. What's available before medication? What complements medication? What supports maintenance? Clear communication drives appropriate utilization.
The most sophisticated employers recognize that GLP-1 coverage represents one tool in a comprehensive metabolic health strategy. They're building benefit designs that acknowledge the full spectrum of employee needs—from prevention through maintenance.
The competitive advantage won't come from having the most generous GLP-1 formulary. It will come from serving the total addressable population with metabolic health needs, not just those who qualify for and choose medication.
